The morning of January 27, 2026, will remain etched in the memory of UnitedHealth Group shareholders as a historic watershed moment. For the first time in over three decades, the American health insurance giant announced revenue guidance for fiscal 2026. This isn't just a temporary setback: it's a tangible sign of a profound transformation the company is undergoing, grappling with structural challenges that are reshaping the landscape of the US healthcare industry.

The numbers released this morning tell a complex story, filled with apparent contradictions and signals that require careful analysis. On the one hand, UnitedHealth reported 12% revenue growth in 2025, reaching $447.6 billion. On the other, guidance for 2026 calls for over $439 billion, well below the $454.6 billion Wall Street had expected. This disappointment caused the stock to tumble 12% in pre-market trading, before closing a more modest 1.30% lower at $351.64.

But let's proceed in order, because behind this data lie dynamics that every investor must understand before making any decisions on UNH stock.

The Fourth Quarter of 2025: When the Numbers Hide the Reality

The fourth quarter marked the culmination of a turbulent year for UnitedHealth. The company faced the devastating impact of a cyberattack in February 2024, which affected its subsidiary Change Healthcare, as well as the consequences of the Biden-era Medicare funding cuts and the effects of the Inflation Reduction Act. To give an idea of the magnitude of these events, in Q4 2025 alone, the company recorded one-time charges of $1.6 billion after taxes.

The table above highlights the paradox of this quarter: while revenues continued to grow in double digits, profitability plummeted dramatically. The medical care ratio, which measures the percentage of premiums spent on healthcare services, exploded to 92.4% from 85.5% the previous year. This means that for every $100 collected in premiums, UnitedHealth had to spend over $92 to cover its policyholders' medical expenses. This razor-thin margin leaves little room for other operating expenses and profits.

What explains this marked deterioration? The causes are multiple and interconnected. First, the return to post-pandemic normalcy has brought a wave of surgeries postponed during Covid-19, from hip and knee replacements to cardiac procedures. Americans, especially those covered by Medicare Advantage, have finally resumed seeking treatment, generating a surge in medical costs that has taken the entire insurance industry by surprise.

But there's more. The cuts to Medicare funding implemented by the Biden administration, combined with the changes introduced by the Inflation Reduction Act to the Part D drug program, have further compressed margins. The company estimates that the transition to the new Medicare V28 coding system alone will cost $6 billion in revenue in 2026, with $2 billion directly impacting UnitedHealthcare and the rest going to Optum.

Guidance 2026: The Moment of Truth

It was the 2026 guidance that triggered the market's most violent reaction. Investors weren't expecting miracles, but they were hoping for signs of stabilization. Instead, UnitedHealth announced projected revenues of more than $439 billion, down 2% from 2025. This decline isn't seen in over thirty years and represents a turning point in the company's strategy.

The gap of nearly $16 billion between analysts' expectations and company guidance is shocking. To put this number into perspective, it's equivalent to the entire annual revenue of many Fortune 500 companies. It's no surprise, then, that the market reacted violently. But what's behind this drastic revision?

DeVeydt identified three main factors during the conference call. The first is the divestment program launched in the fourth quarter of 2025, which includes operations in South America and the United Kingdom. The company has decided to focus on core markets and exit marginal or loss-making businesses. This strategic choice reduces revenue but should improve overall profitability.

The second factor is the expected loss of over 3 million members during 2026. This significant decline reflects both the exit from unprofitable contracts in the Medicare Advantage segment and the impact of changes to Medicaid eligibility criteria in several states. UnitedHealth has chosen to prioritize quality over quantity, abandoning contracts that would have generated revenue but destroyed margins.

The third factor is the impact of Medicare's V28 coding system, which will peak in 2026 before stabilizing in subsequent years. This is the final year of transition, and the company prefers to address it with more disciplined pricing rather than chasing volumes at the expense of profitability.

Optum: Lights and Shadows in the Group Star

While UnitedHealthcare struggles under the weight of medical costs, the Optum segment has shown mixed signals. Overall, Optum generated revenues of $270.6 billion in 2025, up 7% year over year. But this average masks very different performances across the three divisions.

Optum Rx, the pharmaceutical arm, was the brightest star in 2025. With revenues of $154.7 billion (+16% year-over-year) and operating margins of 4.6%, the division benefited from growing prescription volumes, reaching 1.66 billion adjusted prescriptions compared to 1.62 billion in 2024. Operational efficiency and scale allowed Optum Rx to maintain solid profitability despite competitive pressures.

Optum Insight, which provides technology and analytics services to the healthcare industry, saw more modest growth with revenues of $19.4 billion (+4%). High operating margins, projected at around 22.6% for 2026, confirm the division's added value. However, the company had to sustain significant investments in new products and the integration of artificial intelligence, which temporarily compressed profitability from 23.4% in 2024.

The real problem is Optum Health, the integrated and value-based care division. In 2025, Optum Health reported an operating loss of $278 million, down from a profit of $7.8 billion in 2024. The company has decided to radically reorganize this segment, with new leaders and a renewed focus on the value-based care model. By 2026, Optum Health is expected to return to operating profits above $2.2 billion, although $623 million of this will come from the amortization of loss-making contracts acquired in 2025.

What This Means for Investors: Short-Term Scenario

The market's immediate reaction was brutal but understandable. A stock that was worth over $600 in April 2025 is now trading around $350, down 44% from its yearly high. The 12% premarket plunge following the guidance announcement later eased in the regular trading session, a sign that some investors seized the opportunity to accumulate at discounted prices.

In the short term, sentiment around UNH stock is likely to remain weak. Several factors will continue to weigh on prices in the coming months. First and foremost, the Department of Justice investigation into Medicare Advantage billing practices represents a significant unknown. While the company hasn't provided specific details, the mere existence of a federal investigation maintains a high risk premium on the stock.

Second, the market will have to digest the very concept of declining revenues. For a company accustomed to uninterrupted growth for three decades, a 2% decline in revenue represents a paradigm shift that will take time for investors to digest. Although earnings per share are expected to grow in 2026 thanks to improved margins, the revenue growth narrative has been shattered.

Finally, political uncertainty weighs heavily. The Trump administration has already demonstrated its willingness to intervene heavily in the healthcare sector, with proposals ranging from imposing 100% tariffs on patented drugs to changes to subsidies under the Affordable Care Act. Every tweet or presidential statement could trigger wild swings in the stock.

Long-Term Outlook: A Giant in Transformation

Looking beyond the short-term noise, a more nuanced picture emerges. UnitedHealth is undergoing a profound restructuring, but the business's foundation remains solid. The company continues to serve nearly 50 million Americans through UnitedHealthcare and supports over 123 million people through Optum's various divisions. Such operational scale creates competitive advantages that are difficult to replicate.

Management's announced "right-sizing" strategy, while painful in the short term, could prove successful in the coming years. By focusing on core markets and exiting marginal businesses, UnitedHealth aims to progressively improve operating margins. Guidance for 2026 calls for an operating margin of 5.5%, up 130 basis points from the adjusted 4.2% in 2025. If the company achieves this goal, it will demonstrate that its restructuring is working.

Another key element for the future is the expected stabilization of the medical care ratio at 88.8% in 2026, a 30 basis point improvement from 89.1% in 2025. This improvement, though modest, suggests that repricing efforts and benefit design changes are starting to bear fruit. If this trend continues in 2027 and beyond, margins could gradually return to more sustainable levels.

Cash generation remains a key strength. In 2025, UnitedHealth generated operating cash flow of $19.7 billion, equivalent to 1.5 times net income. This robust cash flow allows the company to continue paying dividends (approximately $8 billion expected in 2026) and gradually reduce debt towards its target debt-to-capital ratio of 40%.

On the technology front, the integration of artificial intelligence into Optum's operations represents a significant opportunity to improve efficiency and reduce costs in the medium to long term. The company has invested heavily in this area, and the benefits should gradually materialize in the coming years. The ability to use AI to better predict medical costs, optimize care pathways, and automate administrative processes could become a sustainable competitive advantage.

The Verdict: Opportunity for Those with Stomachs

After analyzing the results and outlook in detail, what conclusions can we draw for investors? UnitedHealth is undoubtedly in a complex transition phase, but dismissing the stock as a basket case would be a mistake. The current valuation of approximately 17 times 2026 projected earnings represents a significant discount compared to the historical average and compared to industry peers.

For investors with a short-term horizon and low risk tolerance, the advice is to wait and see. Volatility will remain high in the coming months, with potential retests of recent lows if further negative regulatory news emerges or if Q1 2026 guidance disappoints again. The stock could find support in the $320-$330 area, while a decisive break above $380-$390 would be necessary to confirm a trend reversal.

For long-term investors willing to accept short-term uncertainty, however, current levels could represent an attractive opportunity for gradual accumulation. The most prudent strategy would be to begin building a position with staggered purchases, without rushing to complete the desired exposure. Waiting for the release of the Medicare 2027 Advance Notice and the Q1 2026 results (expected at the end of April) could provide further insight into whether the investment thesis holds up.

One element not to be underestimated is the dividend. With a yield around 2.5% at current levels and a sustainable payout ratio, UnitedHealth offers a cushion of returns while investors wait for the stock to recover. In an uncertain market environment, this income stream can make a difference in the overall portfolio performance.

The fundamental question every investor must ask is: Does UnitedHealth still have a sustainable competitive advantage in the American health insurance industry? My answer, after analyzing the numbers in depth, is a cautious yes. Its operational scale, vertical integration with Optum, leadership position in Medicare Advantage, and ability to generate robust cash flow are assets that retain value even in a challenging environment.

However, the road to recovery will be long and winding. The company will have to demonstrate, quarter after quarter, that the restructuring is progressing as planned, that margins are effectively stabilizing, and that employee losses are under control. Only when this evidence is clear will the market return to pricing the stock at more generous multiples.

In conclusion, UnitedHealth deserves a place on the watchlists of value investors willing to accept volatility to capture significant upside potential over the next 12 to 24 months. But it's not a stock for everyone, and it's certainly not a bet for those seeking quick gains or sleeping poorly at night when their portfolio fluctuates. As always in stock investing, the key is to know yourself before you know the stock.